In addition to its use for diabetes, semaglutide has been approved as a treatment for obesity under the brand name Wegovy
Leger B, Senese R, Al-Khodairy AW, Deriaz O, Gobelet C, Giacobino JP, Russell AP (2009) Atrogin-1, MuRF1, and FoXO, as well as phosphorylated GSK-3beta and 4E-BP1 are reduced in skeletal muscle of chronic spinal cord-injured patients
These drugs work by mimicking a hormone called glucagon-like peptide 1 (GLP-1), which regulates blood sugar levels and slows down the rate at which food leaves the stomach, often creating the feeling of fullness
Click here to to read this study in NEJM
Theres less published data specifically on GLP-1 use in lupus patients, which means providers are largely reasoning from what we know about lupus biology and GLP-1 mechanisms rather than from direct clinical trials
Good luck to all pharmacists as we navigate this new venture